Publications by authors named "Sohei Muto"
Background: Autoimmune pulmonary alveolar proteinosis (APAP) is a diffuse lung disease that causes abnormal accumulation of lipoproteins in the alveoli; however, its pathogenesis remains unclear. Recently, APAP cases have been reported during the course of dermatomyositis. The combination of these two diseases may be coincidental; however, it may have been overlooked because differentiating APAP from a flare-up of interstitial pneumonia associated with dermatomyositis is challenging.
View Article and Find Full Text PDFArticle Synopsis
- * It has recently been approved in Japan for treating unresectable thymic carcinoma, although there's limited real-world evidence of its effectiveness.
- * A case study showed that a patient with chemotherapy-resistant thymic carcinoma had a strong, 17-month response to a modified dosing schedule of lenvatinib, indicating that strategic dosing can improve outcomes.
Introduction: Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)-ANCA. MPO-ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD).
View Article and Find Full Text PDFEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are standard therapeutic agents for non-small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long-term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression-free survival of 12 months.
View Article and Find Full Text PDFArticle Synopsis
- Obesity is linked to worse outcomes in patients with anti-ARS antibody-related interstitial lung disease (ILD), as it affects lung function and increases disease relapse rates.
- A study involving 58 patients found that obese individuals had lower lung diffusing capacity and higher fat deposits compared to nonobese patients.
- The research highlights the importance of measuring chest fat using CT scans to predict ILD relapses, particularly noting that higher levels of certain fat types correlate with increased disease severity.
Introduction: This study aimed to assess the utility of quantitative high-resolution computed tomography (HRCT) for determining the clinical course of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease (MDA5 ILD).
Method: This study retrospectively analyzed the data of 34 patients with MDA5 ILD to determine the association between the clinical findings and extent of ILD via quantitative CT analysis at baseline and short-term follow-up. Quantified HRCT scores were evaluated as the lung severity score (LSS), percentage of opacity, and percentage of high opacity.